Hemostemix Inc. (CVE:HEM – Get Free Report) shares crossed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of C$0.07 and traded as low as C$0.07. Hemostemix shares last traded at C$0.07, with a volume of 7,000 shares trading hands.
Hemostemix Price Performance
The stock has a market capitalization of C$15.86 million, a P/E ratio of -2.88 and a beta of 0.50. The company has a debt-to-equity ratio of -61.85, a quick ratio of 0.48 and a current ratio of 0.13. The firm has a fifty day moving average price of C$0.07 and a two-hundred day moving average price of C$0.06.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
